Rectify Pharmaceuticals to Present RTY-406 Data at AASLD Liver Meeting

BOSTON, Oct. 22, 2026 /CourierPR/ -- Rectify Pharmaceuticals, Inc., a biotechnology company based in the United States, is set to present groundbreaking research at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place in Denver, Colorado, from November 5 to 9, 2026. The company will showcase preclinical data for its lead hepatobiliary candidate, RTY-406, as part of the Industry Research Showcase session on November 7, 2026, from 8:00 to 9:30 MT.

RTY-406 is an orally administered Positive Functional Modulator (PFM) that targets both ABCB4 and BSEP, making it a dual-acting therapy. The presentation will highlight the candidate's ability to reduce disease-relevant markers in a mouse model and non-human primate, focusing on its potential to address primary sclerosing cholangitis (PSC) and other hepatobiliary diseases. According to the company, RTY-406's dual mechanism of action uniquely targets abnormal bile composition and reduced bile flow, two core pathophysiological drivers of PSC.

Rectify Pharmaceuticals, Inc., founded on the principle of restoring and enhancing membrane protein function, is advancing a novel class of oral, small molecules that can modulate the activity of wild-type and mutated membrane-bound proteins. The company's breakthrough product platform enables the efficient and rapid discovery of first- and best-in-class small molecule therapies with the potential to address membrane protein dysfunction for the treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases.

The presentation will be available on the company’s website in the News section, providing further details on the research and its implications for the treatment of PSC and other hepatobiliary diseases. With the potential to become the first disease-modifying therapy for PSC, RTY-406 represents a significant advancement in the field of hepatobiliary disease treatment.